|Bid||79.76 x 1100|
|Ask||79.77 x 900|
|Day's range||78.60 - 80.28|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||20.23|
|Earnings date||31 Jul 2020|
|Forward dividend & yield||2.44 (3.15%)|
|Ex-dividend date||12 Jun 2020|
|1y target est||93.94|
Nobody will get preferential access to a potential COVID-19 drug developed by vaccine maker Themis Bioscience, which is being bought by U.S. pharmaceuticals firm Merck & Co Inc, the Austrian firm's chief executive said on Thursday. "Merck has already demonstrated in the past ... that it makes vaccines available to anybody who needs them," Erich Tauber told Reuters on Thursday, adding a potential vaccine would be made available globally. "It is one of the reasons why we have decided to cooperate with Merck."
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
The big pharma has finally joined its peers, launching multiple projects aimed at stopping COVID-19 in its tracks.
Stocks jumped Tuesday, and the S&P 500 traded above 3,000 for the first time since March 5, as hopes for an effective coronavirus vaccine combined with optimism over updates around states’ reopenings. Each of the S&P 500 and Dow traded above 2% shortly after market open.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Merck & Co Inc , which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. Merck did not disclose the terms of the acquisition of Themis, a privately held company.
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
LYNPARZA Approved by FDA for Treatment of HRR Gene-Mutated mCRPC That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Merck KGaA said a slight decline in operating earnings was on the cards this year as the coronavirus pandemic weighs on demand for chemicals in TV screens and is putting couples off seeking the German group's fertility treatments. First-quarter adjusted EBITDA gained 27% to 1.2 billion euros, the healthcare and chemicals company said, surpassing an average analyst estimate of 1.1 billion euros in a Refinitiv poll. Chinese patients sought larger prescriptions of Merck's older diabetes and heart drugs for less frequent hospital visits, offsetting lower sales of fertility drugs.
With increasing life expectancies and aging global populations comes higher prevalence of neurodegenerative disease. Merck is betting big on being the pharma company of the future.
Merck's KEYTRUDA Superior to Brentuximab Vedotin , a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
Merck’s KEYTRUDA Plus Chemotherapy Demonstrated Statistically Significant Improvement in PFS Versus Chemotherapy in Certain Patients with mTNBC
New Combination Data for Merck’s KEYTRUDA Demonstrated Clinical Benefit in Stage III NSCLC and Reinforce Long-Term Survival in Metastatic NSCLC